News Archive

Patient Power Interviews Dr. Ruben Mesa about Fedratinib Approval

MPN News | 8/21/19

BREAKING NEWS: The FDA has approved fedratinib as a new treatment option for myelofibrosis patients.

Read More

MPNRF Quoted in Cure Today Magazine

MPN News | 8/20/19

In an article published by CURE Today, MPN Research Foundation's Executive Director, Michelle Woehrle sat down to discuss the FDA's approval of new Myelofibrosis drug Inrebic (fedratinib), the first approved drug for the disease in nearly a decade.

Read More

Breaking: Inrebic (Fedratinib) approved for Myelofibrosis! This becomes the first FDA approved drug for an MPN in nearly a decade

MPN News | August 16 2019

It is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).

Read More

ASH Awards the 2019 William Dameshek Prize

MPN News | 8/8/19

The American Society of Hematology presented Emmanuelle Passegué, Ph.D., of Columbia University Irving Medical Center in New York City with the 2019 William Dameshek Prize for her outstanding contribution to the field of hematology.

Read More

CPI-0610 Demonstrates Activity in MF Patients After Ruxolitinib Failure

MPN News | 08/01/19

A researcher at Mt. Sinai in this video discusses observations from their clinical trial with the drug CPI-0610.

Read More

The MPN Familial Study

MPN News | 7/25/19

We know that myeloproliferative neoplasms may occasionally run in families, but what we don't know is why. The Fleischman Lab, headed by Dr. Angela Fleischman, MD. PhD. in Irvine, CA is seeking to answer that question.

Read More

The Advancement of Targeted Therapy

MPN News | 7/16/19

Since the development of the JAK1/2 inhibitor ruxolitinib, our understanding of MPNs has come a long way. Researchers Bing Li, Raajit K. Rampal, and Zhijian Xiao document the targeted therapies currently in various stages of development,

Read More

Promising Results of New AACR Study

MPN News | 7/3/19

Researchers at the American Association for Cancer Research recently published an article highlighting the restoration of T-cells specific to fighting the CALR mutation in MPN patients.

Read More

How does MDM2 inhibition work to treat MPNs?

MPN News | 7/9/19

Renowned experts Dr. Srdan Verstovsek and Dr. Jason Gotlib discuss MDM2 inhibition as an avenue for the treatment of MPNs and share information on an upcoming MDM2 clinical trial.

Read More

Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in MF patients

MPN News | 6/17/19

Positive safety and early efficacy clinical data was proven during Promedior's Phase 2 study of PRM-151 in MF patients

Read More

Imago BioSciences to Expand Clinical Trial of IMG-7829 for MF Patients

MPN News | 6/17/19

"IMG-7289 has shown tremendous promise to be a meaningful treatment option for myelofibrosis patients, and these data support our clinical program," said Hugh Young Rienhoff, CEO of Imago BioSciences

Read More

Possible New Myelofibrosis Drug Gets Fast Tracked by the FDA

MPN News | 6/5/19

Sierra Oncology announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis.

Read More

MPN Updates from ASCO 2019

MPN News | 6/4/19

This yearly meeting brings together not only oncology professionals from all disciplines but also includes pharmaceutical companies, advocacy groups and more to discuss the latest updates in cancer research and treatment.

Read More

Researchers at Mount Sinai Investigate a Novel Class of Drugs for MPN Patients

MPN News | 5/14/19

Researchers in The Tisch Cancer Institute's Myeloproliferative Neoplasms (MPN) Program at Mount Sinai is investing a novel class of drugs for MPN patients.

Read More

MPNRF Celebrates 1st Annual Founder's Day

MPN News | 5/6/19

The MPN Research Foundation is celebrating our first annual Founder's Day in memory of Robert (Bob) Rosen, the person who started it all almost 20 years ago. Today, May 6th is particularly special as it was Bob's birthday, and we look forward to celebrating his legacy on this day for years to come.

Read More

Clinical Trial for AVID200 Doses First MF Patient

MPN News | 4/25/19

A TGF-Beta inhibitor - AVID 200 - is joining the race for new therapies for myeloproliferative neoplasms.

Read More

MPN Research Foundation's Patient Registry Featured in Cure Today

MPN News | 4/23/19

In an article published by CURE Magazine, Robyn M. Scherber, M.D., M.P.H, assistant professor of medicine in the Department of Hematology and Oncology at UT Health San Antonio MD Anderson Cancer Center, and co-author Michelle Woehrle, the executive director of the MPN Research Foundation sat down to discuss the newest findings from MPNRF's patient registry, myMPN.

Read More

Update on Promising MF Treatment, Momelotinib

MPN News | 4/12/19

Sierra Oncology is planning a new clinical trial for myelofibrosis patients called the MOMENTUM study.

Read More

MPNRF's Spring 2019 Newsletter has arrived!

MPN News | 4/4/19

Catch up on all the latest happenings in the global MPN community!

Read More

What Is This Rare Blood Cancer That Can Cause the Blood to Thicken?

MPN News

Today on the CBS program, "The Doctors," Dr. Travis sits down with Matt, a polycythemia vera patient, and his physical Dr. Ellen Ritchie.

Read More

U.S. FDA Grants Priority Review for Fedratinib - New Drug Application in Myelofibrosis

MPN News | 3/5/19

In a press release published today, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review for Fedratinib.

Read More

It's Rare Disease day AND a MATCH day!

MPN News | 2/28/19

The MPN Research Foundation is doing our part to advocate for the MPN patient population. The needs of patients are first and foremost in our minds when we choose what researchers to support, have conversations with the FDA, and raise awareness about these rare blood cancers.

Read More

Exciting Announcement from MPNRF!

MPN News | 2/19/19

This fall, in collaboration with MPN Advocacy & Education Int'l, The Leukemia & Lymphoma Society and UT Health San Antonio MD Anderson Cancer Center, MPNRF will be holding an externally led patient-focused drug development (PFDD) meeting with the U.S. Food and Drug Administration (FDA).

Read More

Breaking news on ropeginterferon for PV patients

MPN News | 2/21/19

Click here to read the entire press release.

Read More

Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs

MPN News

​Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs

Read More

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

MPN News

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first 2 years and hence we aimed to analyze the outcome of 2-year disease-free survivors.

Read More

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen

MPN News

Although allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for myelofibrosis (MF), data are limited on how molecular markers predict transplantation outcomes. We retrospectively evaluated transplantation outcomes of 110 consecutive MF patients who underwent allo-HCT with a fludarabine/melphalan (Flu/Mel) conditioning regimen at our center and assessed the impact of molecular markers on outcomes based on a 72-gene next-generation sequencing panel and Mutation-Enhanced International Prognostic Scoring System 70+ v2.0 (MIPSS70+ v2.0).

Read More

New Predictive Model Developed for Leukemic Transformation in Primary Myelofibrosis

MPN News

"Primary myelofibrosis (PMF) can be treated with allogenic stem cell transplant (which can cure the disease or prolong survival) or with drug therapy, splenectomy, and radiation. Determining the appropriate time for a transplant is an important objective in tailoring treatment to the individual patient, and currently, the mutation- and karyotype-enhanced prognostic scoring system (MIPSS70 + version 2.0), a risk model for overall survival, is one tool used to do so. A recent study sought to develop a complementary, robust predictive model for patients whose disease will transform into acute myeloid leukemia, a complication that is associated with a poor prognosis."

Read More

Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis.

MPN News

Myelofibrosis in myeloproliferative neoplasms (MPNs) with mutations such as JAK2V617F is an unfavorable sign for uncontrollable disease progression in the clinic and is complicated with osteosclerosis whose pathogenesis is largely unknown. Because several studies have revealed that macrophages are indispensable supporter for bone forming osteoblasts, we speculated that macrophages might play a significant role in the proliferation of collagen-producing myofibroblasts in marrow fibrotic tissues. Here, we show that myelofibrosis critically depends on macrophages whose differentiation is skewed by vitamin D receptor (VDR) signaling.

Read More

Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling.

MPN News

Background: Janus Kinase 2 (JAK2) plays pivotal roles in signaling by several cytokine receptors. The mutant JAK2 V617F is the most common molecular event associated with myeloproliferative neoplasms. Selective targeting of the mutant would be ideal for treating these pathologies by sparing essential JAK2 functions.

Read More

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.

MPN News

Constitutive JAK2 signaling is central to myeloproliferative neoplasm (MPN) pathogenesis and results in activation of STAT, PI3K/AKT, and MEK/ERK signaling. However, the therapeutic efficacy of current JAK2 inhibitors is limited.

Read More

Malignant bone marrow disease: New hope for MPN patients

MPN News

"Myeloproliferative neoplasms (MPNs) are still difficult to treat. A team from Vetmeduni Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences/Medical University of Vienna has discovered a new therapeutic approach that could fundamentally change this situation, as evidenced by a study that was published recently in the academic journal Blood."

Read More

Are you ready to roll up your sleeves?

MPN News | 2/12/18

The MPN Research Foundation is doing our part to advocate for the MPN patient population. The needs of patients are first and foremost in our minds when we choose what researchers to support, have conversations with the FDA, and raise awareness about these rare blood cancers.

Read More

Rare Disease Day 2019 Kickoff

MPN News | 2/4/18

#BecomeAnAdvocate #ShowYourStripes #RareDiseaseDay #MPNRF

Read More

Promising Results Released from Clinical Trial for MF Patients

MPN News | 1/7/19

According to a press release published by Constellation Pharmaceuticals, the latest findings in the Manifest Clinical Trial of CPI-0610 in Myelofibrosis Patients was found to have a profound effect on trial participants.

Read More

MPNRF Releases 2019 Request for Proposals

MPN News | 1/7/19

The MPN Research Foundation is proud to announce the opening of our 2019 call for proposals for the MPN Challenge Grant Program.

Read More

Breaking news for ropeginterferon

MPN News | 12.17.18

The CHMP has given a positive opinion on the drug and recommended granting market authorization.

Read More

MPN Highlights from ASH 2018

MPN News | 12/5/18

Each year the American Society of Hematology (ASH) hosts their annual convention, where researchers, doctors, and organizations such as the MPN Research Foundation gather to discuss the ever-changing world of blood disorders and learn about the progress of research.

Read More

MPNRF Founder Bob Rosen Honored as MPN Hero

MPN News | 12/1/18

The MPN Heroes Celebration Event held annually at ASH is an opportunity to recognize the individuals and organizations who work hard on behalf of the MPN community and make a difference in the lives of patients living with PV, ET, and MF. Each year at this event, recipients of the MPN Heroes Recognition Program are honored based on those actions and traits that define them as heroes. This year, on November 30, 2018, the founder of the MPN Research Foundation, Bob Rosen, was honored as one of those heroes.

Read More

MPNRF Funded Abstracts to be Presented at ASH

MPN News | 11/19/18

With your support, we have funded research that has resulted in gains in our understanding of Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis. The publications linked below are funded by MPNRF and will be presented at the American Society of Hematology annual meeting in San Diego this December.

Read More

Study Assess Current Recommended Guidelines for the Treatment of PV Patients

MPN News | October 31, 2018
Read More

University of Michigan seeks to make bone marrow imaging less painful for people with myeloproliferative neoplasms

MPN News | October 23, 2018

Patients with an MPN are invited to participate in the non-invasive study

Read More

Ropeginterferon reduces JAK2 burden compared to Hydroxyurea in PV according to new study

MPN News | October 15, 2018

After 1 year of treatment with ropeginterferon, the ratio of JAK2-mutated to wild-type colonies grown from bone marrow progenitors was reduced by 64%, compared to 25% in patients receiving hydroxyurea.

Read More

Classification and Prognostic Models Developed for MPN Patient Outcomes

MPN News | 10/11/18
Read More

Increased Pentraxin-3 Correlates with the Activity of the Neoplastic Clone in Primary Myelofibrosis

MPN News | December 7, 2017

Increased Pentraxin-3 Correlates with the Activity of the Neoplastic Clone in Primary Myelofibrosis

Read More

FDA awards $18 million in grants for advancing treatment of rare diseases

MPN News | 10/3/18

The FDA announced on that they have awarded 12 new clinical trial research grants toward advancing the development of treatments of rare diseases.

Read More

Behind the Mystery: Living with Polycythemia Vera

MPN News

MPN experts Dr. Richard T. Silver, from New York - Presbyterian/Weill Cornell Medical Center, and Dr. Srdan Verstovsek of the MD Anderson Cancer Center, to discuss the latest in patient care and clinical trials for polycythemia vera, as well as the future for those living with PV as a chronic illness.

Read More

Janssen Elects Not to Continue Agreement with Geron for Imetelstat

MPN News

Today Janssen announced that they would no longer be partnering with Geron on the development of Imetelstat

Read More

MPN Research Foundation Attends 3rd Annual MPN Horizons Conference

MPN News | September 11, 2018

Director of Development, Bill Crowley, and Executive Director, Michelle Woehrle, represented MPN Research Foundation at the recent MPN Horizons 2018 Conference in Prague, Czech Republic.

Read More

MPN Research Foundation's SCT Spectrum Transplant Timing Tool featured in CURE Today

MPN News | August 20, 2018
Read More

Recent Study Indicates a Familial Predisposition for MPN

MPN News | August 15 , 2018

A recent analysis of the Swedish Cancer Family Database has found that there is a familial predisposition for certain blood cancers, including myeloproliferative neoplasms.

Read More

MPN Research Foundation's Patient Registry Featured in CURE Today.

MPN News | July 23, 2018

Registry Manager, Lindsey Whyte, discusses the benefits that myMPN brings to MPN patients and researchers with CURE Today.

Read More

MPN Research Foundation Launches Stem Cell Transplant Timing Tool for MPN Patients

MPN News | July 19, 2018

The goal of the SSTT tool is to increase successful stem cell transplant outcomes by decreasing the number of delayed transplant for MPN patients.

Read More

Dr. Ruben Mesa Featured in Rare Diseases Report Magazine

MPN News | June 26, 2018

Dr. Mesa discusses updates on emerging innovations, his views about the greatest obstacles facing the treatment of rare diseases & his support for the working as a team when treating MPNs

Read More

Interferon Changes Life of Essential Thrombocythemia Patient, Karrie Schwartz

MPN News | June 25, 2018

Stories like Karrie's are the reason MPNRF is dedicated to investing time and resources into opportunities for repurposing existing drugs and figuring out the mechanisms of action that lead to results.

Read More

Data from myMPN Patient Registry Presented at 23rd Annual EHA Congress

MPN News | June 21, 2018
Read More

Molly Rosen Guy, daughter of MPNRF founder, Bob Rosen, shares her story of grief after losing her dad

MPN News
Read More

Screening for B cell clone prior to taking a JAK2 inhibitor suggested

MPN News | June 15, 2018

Austrian researchers find elevated risk for Lymphoma risk elevated in some with MF

Read More

HikeMF 2018 Raises $35,000 for MPN Research Foundation!

MPN News | June 8, 2018

The MPN Research Foundation is grateful to Julie, Lori and their team of volunteers who made this event possible. This year all proceeds benefit the MPN Research Foundation’s Challenge Grants program!

Read More

MPNRF hosts meeting of the minds on the future of immunotherapy in MPN

MPN News | June 7, 2018

MPNRF hosts experts in the areas of MPN clinical practice, MPN research and immunotherapy with the goal to hear about ongoing work in the area of immunotherapy in MPNs.

Read More

Dr. Srdan Verstovsek presents results from Ropeginterferon vs Hydroxyurea study at MPN Asia 2018

MPN News | May 9, 2018

After a 2 year study, Ropeginterferon proves more effective than Hydroxyurea in symptom improvement and lowering progression rates

Read More

Free webinar for MPN patients and caregivers

MPN News | April 23, 2018

NCCN to host 2 events focused on education

Read More

myMPN data shows trends for PV, ET and MF

MPN News | April 16, 2018

Users with PV, ET and MF are entering symptom data across the country

Read More

MPN Alliance Australia and MPN Research Foundation Partner to support research

MPN News

MPNAA and MPNRF work together to better understand interferon

Read More

Blood article by MD Anderson researchers looks back at 107 MF patients who discontinued Jakafi

MPN News | March 22, 2018

Authors describe epigenetic mutations in some patients and suggest follow up research is needed

Read More

CR&T Shares videos from their 8th International MPN conference

MPN News | March 6, 2018

Watch video updates from MPN experts

Read More

CTI Biopharma expands it's clinical Trial

MPN News | March 1, 2018

CTI Biopharma is recruiting patients for the PAC203 study, a randomized phase 2 trial evaluating different doses of pacritinb in myelofibrosis patients. Previously, patients had to have a platelet count less than 100,000.

Read More

Recognizing some of the women in the MPN community

MPN News | March 6, 2018

March 8th is International Women's Day

Read More
MPN News | February 28, 2018

“Beyond Blue,” a short documentary by an award‐winning filmmaker, debuts to raise awareness of MPNs

Read More

Constellation Pharmaceuticals announced a Phase 2 study of CPI-0610 in patients with myelofibrosis.

MPN News | March 7, 2018

Constellation Pharmaceuticals announced a Phase 2 study of CPI-0610 alone or in combination with ruxolitinib in patients with myelofibrosis.

Read More

Asana BioSciences Announces a Phase II trial in patients with MF

MPN News | February 14, 2018

Asana BioSciences announces a Phase II study in patients with myelofibrosis is in progress in the US.

Read More

Read about the life of the Founder of MPNRF

MPN News | January 12, 2018

Obituary for Robert Rosen, Founder of the MPN Research Foundation

Read More

Celgene buys maker of Fedratinib

MPN News | January 9, 2018

Fedratinib may be approved for patients resistant to or intolerant of Jakafi

Read More

Two MPN experts discuss ASH 2017

MPN News | December 21, 2017

Return of old drugs, update to prognostic scoring system and more

Read More

Video updates from ASH 2017

MPN News | December 19, 2017

Four experts weigh in on the MPN updates

Read More

Ruxolitinib trial for Essential Thrombocythemia now enrolling patients

MPN News | November 13, 2017

Focus is on Hydroxyurea resistant/ intolerant ET

Read More

Patient Power webinar features PV patient discussing myMPN

MPN News | November 14, 2017

Dr. Srdan Verstovsek and MPNRF's Lindsey Whyte discuss new tool for patients

Read More

MPNRF Pursues Bold New Initiative: The Progression Marker Project

MPN News | 11/13/2017

MPNRF is launching a much needed initiative that could unlock answers about the rare blood cancer myeloproliferative neoplasms and identify new therapeutic targets.

Read More

NCCN develops patient-friendly MPN guidelines

MPN News | October 19, 2017

NCCN Guidelines for Patients are written in plain language and include patient-friendly tools.

Read More

New drug trial for Polycythemia Vera initiated by Roche

MPN News | October 18, 2017

Idasunutlin is in Phase 1 and enrolling patients now

Read More

A new study to explore the practicality and preliminary effects of two different non-pharmacologic strategies for MPN patient symptom burden

MPN News | September 28, 2017

Arizona State University, in partnership with University of Texas Health San Antonio Cancer Center, and the Mayo Clinic are seeking MPN patients to participate in an 8-week study that aims to explore the practicality and impact of different non-pharmacologic strategies (i.e., mobile app, education) to reduce fatigue in MPN patients.

Read More

MPNRF visits the FDA

MPN News | September 18, 2017

The FDA reached out to 3 MPN patient advocate groups including the MPN Research Foundation, had discussions about the concerns of MPN patients, and asked them to send representatives to an FDA Mini Symposium:

Read More

The MPN Interferon Initiative

MPN News | September 26, 2017

MPNRF goes after the JAK2 mutation and the mysteries of Interferon with new project

Read More
MPN News
Read More

September is Blood Cancer Awareness Month

MPN News | August 30, 2017

MPNRF has a few ways for you to take action

Read More

What does the approval of Kymriah mean for MPN?

MPN News | September 1, 2017

MPNRF asks immunotherapy expert Saar Gill about what we can expect

Read More
MPN News
Read More

MPN Landmark Survey

MPN News | July 20, 2017

MPN Landmark Survey funded by Incyte Corporation has been released

Read More

2017 Winners of the MPN Challenge Grant announced

MPN News | August 28 2017

Five projects focused on MPN research

Read More

Digital Sherpa Workshops

MPN News | July 19, 2017

Join Patient Empowerment Network and MPN Research Foundation for Digital Sherpa Series

Read More

Follow up on the CALR mutation discovery

MPN News | July 7, 2017

Dr. Hasselbach describes CALR as an immunotherapy target in new Leukemia submission.

Read More

BREAKING NEWS

MPN News | June 26, 2017

AOP Orphan and PharmEssentia announces its latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera

Read More

Congratulations to Dr. Mesa on his Exciting Move

MPN News | June 13, 2017

Dr. Mesa move to UT Health Center

Read More

The MPN Challenge RFP is now open

MPN News | February 16, 2017

Apply for a grant now

Read More

The Mayo Clinic Is Seeking MPN Patients for Nutrition Survey

MPN News | 2/8/2017
Read More

Drs. Mullally and Mead describe in Blood the dominance of mutated cells.

MPN News | February 7, 2017
Read More

Remembering Robert Tollen, pioneer in MPN support.

MPN News | February 6, 2017
Read More

Pacritinib taken off FDA clinical hold.

MPN News | 1/5/2017

CTI BioPharma will start a new trial, PAC203 for Myelofibrosis

Read More

Phase 2 study combines Ruxolitinib and Decitabine for people with MPN

MPN News | December 21, 2016

Phase 2 study combines Ruxolitinib and Decitabine for people with MPN

Read More

Share your experience with Essential Thrombocythemia (ET) to help shape the future of treatment

MPN News | 12/12/2016

This research study is by QuintilesIMS (sponsored by Incyte Corporation) Background QuintilesIMS Global Services, a worldwide consulting firm, is conducting a research study to better understand the experience of ET patients. QuintilesIMS plans to interview patients who have been diagnosed with ET one‐on‐one over the phone. QuintilesIMS is looking for interested people to share what they have gone through since being diagnosed with ET. Purpose The overall purpose of the study is to learn which symptoms of ET are the most common, and how these symptoms typically affect the lives of patients like you who live with the disease. This understanding may help improve how the patient’s experience is accounted for in clinical trials that measure the effect of disease treatments. It also may help patients and their families by highlighting the consequences of the disease that most need greater attention, possibly leading to the development of new programs and support services.

Read More

MPN highlights from ASH's annual meeting

MPN News | December 12, 2016

MPN highlights from ASH's annual meeting

Read More

Katya Ravid makes discovery on using MRI to detect myelofibrosis

MPN News | November 21, 2016
Read More

New NCCN Guidelines outline diagnosis, treatment strategies for MPNs

MPN News | September 30, 2016

NCCN Guidelines document evidence-based consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive care services that are most likely to lead to optimal outcomes.

Read More

CTI reports topline data for PERSIST-2 in the hopes of lifting FDA hold in coming months.

MPN News | August 30th, 2016

CTI BIOPHARMA Announces top-line results from PERSIST-2 Phase 3 trial of Pacritnib for high-risk patients with advanced myelofibrosis

Read More

ASH announces seventh-round bridge grant recipients

MPN News | July 21st

MPN Research Foundation congratulates our MPN Challenge grantees Zhijian Qian, a PhD from the University of Illinois at Chicago and Ann Mullally,a MD at The Brigham and Women's Hospital for receiving the 2016 ASH Bridge Grant.

Read More
MPN News | March 1, 2014
Read More

Anti-fibrotic drug PRM-151 recruiting MF patients across the country

MPN News | July 4, 2016

The PROMOTE site has information on their clinical trial including which sites are actively recruiting people who have myelofibrosis.

Read More

Stanford and 23andMe partner on MPN

MPN News | July 5, 2016

Reported in Blood, 726 people with Polycythemia vera, essential thrombocythemia and myelofibrosis were compared to a control group.

Read More
MPN News
Read More

Vice President Joe Biden addresses the 2016 ASCO audience

MPN News | June 7, 2016

The Cancer Moonshot is a new push for more teamwork in cancer research and application of innovation.

Read More

MPN updates from ASCO 2016

MPN News | June 8, 2016

Updates on clinical trials and research news for PV, ET and MF.

Read More

Gilead sponsors observational study on MPNs

MPN News | August 2, 2016

A research project sponsored by Gilead is currently seeking participants for a study about experience with MPN symptoms.

Read More

FDA OK's Pacritinib for some patients; Full clinical hold remains

MPN News | March 14, 2016

Pacritinib remains on full clinical hold, but per FDA patients receiving benefit are allowed to receive the drug under a Single Patient IND (SPI)/Compassionate use program.

Read More

New research out of UIC suggests racial disparities among those with MPN

MPN News | March 11, 2016

Researchers from the University of Illinois at Chicago have just published a study that demonstrated a difference between Caucasians and non-Caucasians for those with myeloproliferative neoplasms.

Read More

Medicare Approves Coverage for SCT

MPN News | February 19, 2016

Medicare has (somewhat) come through for people with Myelofibrosis by agreeing to provide coverage for those who qualify and are in need of a Stem Cell Transplant.

Read More

Update: Pacritinib Now on Full Clinical Hold

MPN News | February 10, 2016

The FDA has put the Phase 3 trials of Pacritinib on full clinical hold, noting overall survival results.

Read More

Zebrafish Shines Light on Melanoma and Provides Hope for MPN

MPN News | February 11, 2016

Dr. Leonard Zon of Boston Children's Hospital has made a discovery that shed light on the origins of cancer.

Read More

Blood Journal Reports that CALR Mutation Reduced with Pegasys

MPN News | December 11, 2015

In the journal Blood, Jean-Jacques Kiladjian and colleagues reported their findings that Pegylated interferon alpha induces hematological and molecular remission in CALR mutated essential thrombocythemia patients.

Read More

Cure Magazine honors MPNRF with MPN Hero honor

MPN News | December 10, 2015

Each year for the past three years, Cure Magazine and Incyte Corporation have recognized efforts within the MPN community with their MPN Hero award.

Read More

Research updates from ASH 2015

MPN News | December 8, 2015

Here is a selection of presentations made during the American Society of Hematology annual meeting.

Read More

TAKE ACTION NOW FOR MYELOFIBROSIS

MPN News | November 17, 2015

On October 29, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule allowing Medicare coverage for stem cell transplants in approved clinical trials for Myelofibrosis (MF) patients. Unfortunately, some of the requirements in the proposed rule would actually decrease access to stem cell transplants.

Read More

Nature Medicine: Drug stops reproduction of cancer cells in Myelofibrosis

MPN News | November 17, 2015

According to a paper published in Nature Medicine, the drug MLN8237 (or Alisertib) has reduced tumor cells, blood counts and fibrosis in mouse models of myelofibrosis.

Read More

2015 Gene editing success in UK with incurable leukemia

MPN News | November 6, 2015

Today from the U.K. came the exciting news that an infant with incurable, aggressive leukemia has had her cancer reversed with experimental gene editing.

Read More

Thank you.

MPN News | September 30, 2015

It's the last day of September, and we've worked hard over the past four weeks plus to raise awareness about the need for research funding and care for people living with Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis.

Read More

CTI Biopharma to submit NDA for Pacritinib

MPN News | September 23, 2015

CTI BioPharma Corp. today announced their plan to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Pacritinib, an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R.

Read More

Yoga and MPN

MPN News

Dr. Jennifer Huberty's research lab, in partnership with the Mayo Clinic and UDAYA Entertainment Inc., is conducting a research study to explore the preliminary effects of a home-based, online-streamed yoga intervention on symptoms and quality of life within Myeloproliferative Neoplasm (MPN) cancer patients.

Read More

NEJM reports normalized blood counts for people with ET enrolled in Imetelstat study

MPN News | September 3, 2015

A new study from NEJM (Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia, N Engl J Med 2015; 373:920-928 September 3, 2015) reports that all 18 ET patients in a Phase 2 trial treated with the drug imetelstat exhibited decreased platelet levels, and 16 showed normalized blood cell counts.

Read More

BMS buys rights to PRM-151 and Promedior

MPN News | August 31, 2015

Bristol-Myers Squibb has bought rights to a fibrosis drug and its privately held developer - Promedior.

Read More

Executive Director

MPN News | August 1,2015

We are pleased to announce that effective 8/1/2015, Michelle Woehrle has assumed the role of Executive Director of the MPN Research Foundation.

Read More

Let's change your prognosis

MPN News | August 18, 2015

You may have noticed a change to our logo and tagline, which went live Tuesday August 18th.

Read More

Article in Modern Pathology on Interferon and its effect on bone marrow fibrosis in people with Myelofibrosis

MPN News | August 14, 2015

An article in Modern Pathology by Marco Pizzi, Richard T Silver, Ariella Barel and Attilio Orazi discussed their findings from a retrospective study, that recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis.

Read More

2015 MPN Challenge Grant Awards

MPN News | August 11, 2015

"The best thing we can do as a patient-driven organization funding our own research is to entice the best minds in science to focus on PV, ET and MF lest they get left by the wayside" says MPN Research Foundation President Barbara Van Husen.

Read More

Leaders from the MPN medical community take on the high cost of cancer drugs

MPN News | August 6, 2015

On July 28th we shared a story on Facebook about an initiative including dozens of blood cancer thought leaders who joined together to support a petition to lower the cost of cancer drugs.

Read More

2015 EHA news on MPNs

MPN News | June 25, 2015

Ciro Rinaldi presented a poster on Essential Thrombocythemia:GATA-1, BUT NOT FOG-1, FLI-1 OR CALR, IS UP-REGULATED IN ESSENTIAL THROMBOCYTHEMIA INDEPENDENTLY FROM JAK2 AND CALR MUTATIONS

Read More

With Research There Is Hope

MPN News

On August 19, 2014, Julie Libon was diagnosed with Myelofibrosis. She learned that MF is a rare blood cancer that affects approximately 16,500 to 18,000 people in the United States with no cure and no treatments to slow down the progression of this disease.

Read More

2015 ASCO news

MPN News | June 5, 2015

The American Society of Clinical Oncology has its big meeting each year in Chicago in early June. In the past solid tumor cancers have received the most attention, saving blood cancer announcements for the American Society of Hematology meeting where the focus is more narrow.

Read More

Promise and possibility

MPN News | February 25, 2015

Last week we issued a call for proposals for our 2015 grant program, which we run with with some help from the Leukemia & Lymphoma Society, but is largely funded by patients around the world.

Read More

NEJM study on the effect of mutation order in MPNs

MPN News | February 12, 2015

The order in which someone with an MPN acquires a genetic mutation may effect their prognosis, says an article published today in the New England Journal of Medicine.

Read More

MPNRF Initiates CRISPR Project

MPN News | February 10, 2015

One of the primary goals of the MPN Research Foundation is to catalyze new avenues of research into the cause(s) and potential treatments for the blood cancer group polycythemia vera, essential thrombocythemia and myelofibrosis.

Read More

2015 World Cancer Day

MPN News | February 4, 2015

Today is World Cancer Day. In honor of this day recognizing the struggle of cancer patients everywhere we're asking people to give a gift for MPN research that will help identify better treatments and eventually a cure for polycythemia vera, essential thrombocythemia and myelofibrosis.

Read More

MPDRC newsletter for January 2015

MPN News | January 29, 2015

The MPD Research Consortium has just issued its most recent newsletter.

Read More

NEJM reports on randomized trial of Ruxolitinib vs phlebotomy in Hydroxyurea-resistant PV

MPN News | January 29, 2015

The New England Journal of Medicine has just published a paper co-authored by Claire N. Harrison, D.M., Ruben Mesa, M.D. and Srdan Verstovsek, M.D., Ph.D. among others, describing the outcome of a trial measuring Ruxolitinb in polycythemia vera patients who are intolerant or who do not respond to Hydroxyurea.

Read More

Tamoxifen possible treatment for myeloproliferative neoplasms

MPN News

Researchers at the National Center for Cardiovascular Research (CNIC) in Spain found that estrogens play a role in regulating the active of blood stem cells from bone marrow.

Read More

Jakafi approved for use in Hydroxyurea-resistant polycythemia vera

MPN News | December 4, 2014

Today Jakafi became the first FDA-approved treatment for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.

Read More

Gary Gilliland named director at the Fred Hutchinson Cancer Research Center

MPN News

The MPN Research Foundation is proud to congratulate Gary Gilliland today on his appointment as Director of the Fred Hutchinson Cancer Research Center in Seattle.

Read More

Nov. 2014 update on Cap the Copay

MPN News | November 18, 2014

Myelofibrosis patient Bill Erickson is in the news for his support of the Cap the Copay Coalition, an Illinois initiative which seeks to reduce the costs people taking specialty tier medications must pay out of pocket.

Read More

2014 Promedior fast track

MPN News

The FDA has granted Fast Track designation to PRM-151 for the treatment of myelofibrosis (MF), a serious, life-limiting cancer characterized by fibrosis of the bone marrow.

Read More

2014 FDA Removes Clinical Hold on Geron's Imetelstat

MPN News

Geron Corporation (Nasdaq: GERN) announced on November 3rd that the FDA)has removed the full clinical hold on their investigational new drug application for imetelstat.

Read More

2014 Shire approved for Agrylin

MPN News | October 2, 2014

Shire Japan KK announced that the Japanese MHLW (Ministry of Health, Labour and Welfare) has approved AGRYLIN® (anagrelide hydrochloride) for the treatment of essential thrombocythemia.

Read More

Samples sought by Angela Fleischman, UC Irvine

MPN News | September 24, 2014

Dr Angela Fleischman has opened a MPN research laboratory at University of California – Irvine.

Read More

Fibrosis: Focus Area Two

MPN News

I’m often asked to explain what exactly is bone marrow fibrosis.

Read More

Immunotherapy: Focus Area Three

MPN News

The immune system is made up of many types of cells and secreted factors that act together to defend against infections and remove damaged tissues.

Read More

2014 MPN study by Gilead and Evidera

MPN News | September 18, 2014

Gilead Sciences, Inc is sponsoring a qualitative research study to evaluate the Modified Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) in an electronic format.

Read More

Jen's Caregiver Story - ET

MPN News | September 15, 2014

This is a tattoo I got for my daughter who has an MPN.

Read More

2014 Why we created Tims Run

MPN News

My husband Tim, a firefighter for 33 years with the Portland Fire Department, an avid gardener, outdoorsmen and family man passed away August 30, 2011 at only 63 years old, following a courageous fight against Myelofibrosis.

Read More

CALR Mutation: Focus Area One

MPN News

As a board member of the MPN Research Foundation for more than 10 years, it has been encouraging to see the progression of the scientific community’s understanding of the MPNs and the development of an initial set of targeted therapies.

Read More

Study hints at potential of combination therapy for polycythemia vera

MPN News | September 4, 2014

We have been interested in the potential of combination therapy for treatment of MPNs and are pleased to see some initial findings released.

Read More

PCORI survey

MPN News | September 3rd, 2014

MPN Research Foundation is partnering with the Patient-Centered Outcomes Research Institute (PCORI) and the American Institutes for Research (AIR) to conduct a survey of adults with rare and/or chronic conditions.

Read More

September is Blood Cancer Awareness Month

MPN News | September 1, 2014

I know that it seems like there's a month or day for everything, from Hamburger Day to Dental Hygienist Appreciation Week, but there are really good reasons to have a month for Blood Cancer Awareness, particularly if you have Polycythemia Vera, Essential Thrombocythemia or Myelofibrosis.

Read More

PromediorOrphanStatus2014

MPN News | September 2, 2014

Promedior, Inc. has been granted orphan drug designation for PRM-151 for the treatment of myelofibrosis by the U.S. Food and Drug Administration (FDA).

Read More

FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis

MPN News | August 5, 2014

CTI BioPharma has been granted Fast Track designation by the FDA for pacritinib for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are not as well managed on other JAK2 therapy.

Read More

2014 MPNRF joins Cap the Copay initiative in Illinois

MPN News | July 31, 2014

The MPN Research Foundation has joined forces with a coalition of patient advocacy organizations who seek to reduce the disparity in copays for people on specialty medication.

Read More

Annual Al Bolea Memorial Ride

MPN News

This ride is in memory of the late Al Bolea who lost his gallant fight against Myelofibrosis on September 23, 2005.

Read More

2014 ATSDR announces more findings from PV cluster in Pennsylvania

MPN News | July 29, 2014

The Agency for Toxic Substances and Disease Registry (ATSDR) recently released more data following their study of a Polycythemia Vera cluster that was found in the Tri-County area in Pennsylvania.

Read More

2013: CALR genetic mutation discovered for MPN

MPN News | December 10, 2013

MPN Research Foundation grantee Robert Kralovics was one of two labs to discover a new genetic mutation that accounts for most of the cases of JAK2 negative MPN patients.

Read More

2014 BloodCenter of Wisconsin Launches CALR Test for MPN

MPN News | July 30, 2014

Following up on the discovery of a new genetic mutation for MPNs, several institutions now have CALR diagnostic tests available, including the BloodCenter of Wisconsin.

Read More

2014 Summer Science Update

MPN News

If it’s summer, it’s time for two important meetings where researchers present their latest findings on MPNs: In the US, it’s the American Society of Clinical Oncology (ASCO) meeting, and in Europe it’s the European Hematology Association Meeting (EHA). Here’s a brief summary of key findings:

Read More

2014 MPN Challenge Grants Award $1 million in Research Funding

MPN News | July 1 2014

The MPN Research Foundation and The Leukemia & Lymphoma Society (LLS) are proud to announce that ten new research projects will receive funding through their collaboration, renamed MPN Challenge in 2014.

Read More

2014 CNIC discovers expanded role of bone marrow micro-environment for MPNs

MPN News | June 23, 2014

The Stem Cell Physiopathology group at the CNIC (the Spanish National Cardiovascular Research Center), led by Dr. Simón Méndez–Ferrer has shown that the micro-environment of the bone marrow is a good target for therapeutic options for people with myeloproliferative neoplasms.

Read More

FDA removes hold on imetelstat trials in MF

MPN News | June 12, 2014

Geron Corp. announced today that the FDA has removed the partial clinical hold on its clinical trial of imetelstat in myelofibrosis.

Read More

The Critical Importance of Clinical Trials

MPN News | June 4, 2014

Haematologica recently published a thought-provoking article by Drs. John Mascarenhas and Ronald Hoffman of Mt. Sinai, Dr. Ruben Mesa of the Mayo Clinic, Scottsdale, and Dr. Josef Prchal of the University of Utah, (Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials) which gives a history of treatments for essential thrombocythemia and polycythemia vera, and also makes the case that there is insufficient scientifically valid evidence on the treatment options currently available.

Read More

The Critical Importance of Clinical Trials

MPN News | June 4, 2014

Haematologica recently published a thought-proviking article by Drs. John Mascarenhas and Ronald Hoffman of Mt. Sinai and the MPD-RC, (Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials) which gives a history of treatments for essential thrombocythemia and polycythemia vera, and also makes the case that there is insufficient scientifically valid evidence on the treatment options currently available.

Read More

2014-5-21-AgentOrangeMPNAE

MPN News | May 21, 2014

MPN Advocacy and Education International is searching for Vietnam Veterans who were exposed to Agent Orange and now have a diagnosis of Myelofibrosis, Polycythemia Vera, or Essential Thrombocythemia (Myeloproliferative Neoplasms-MPNs).

Read More

Pegasys Update

MPN News | April 8, 2014

The primary use of Pegasys over the years has been for the treatment of Hepatitis C.

Read More

Geron Imetelstat trial put on hold by FDA

MPN News

Geron has been given verbal notification from the U.S. Food and Drug Administration (FDA) that its application for imetelstat has been placed on full clinical hold, affecting all ongoing company-sponsored clinical trials.

Read More

JAK Inhibitors and JAK2 Mutation: What's the Connection?

MPN News | February 6, 2014

From MPN Focus, a newsletter from the Clinical Research Center for MPNs at MD Anderson Cancer Center

Read More

Zebra coalition petitions FDA

MPN News | February 4, 2014

A petition spearheaded by the Zebra Coalition, brought together by MPNforum, asks that the FDA require a Patient Advocate be available at every Investigative New Drug clinical trial site to provide a needed level of Patient safety.

Read More

MPN Hero Designates $25,000 for Research

MPN News | January 29, 2013

In 2013, Incyte Corporation (the makers of Jakafi) in collaboration with CURE Media Group, established a program to honor members of the MPN community.

Read More

MPNRF Attends One Voice Against Cancer's Annual Meeting

MPN News

On January 13, 2014 The MPN Research Foundation sent its Deputy Director Michelle Woehrle and MF patient Patrick Corcoran to OVAC's annual meeting to advocate on behalf of people living with PV, ET, and MF.

Read More

House and Senate Appropriations Increase Funding for NIH and NCI

MPN News | January 20, 2014

House and Senate Appropriations Chairs Hal Rogers and Barbara Mikulski released their FY 2014 omnibus appropriations bill last week.

Read More

Thank you for Giving Tuesday 2013

MPN News

Giving is as important as receiving during the holiday season. This season has not been easy…a typhoon hit the Philippines, deadly tornadoes in the Midwest and snow in the West and East coast. Many people are worried about the economy and jobs.

Read More

PRM 151 Recruiting MF patient

MPN News | December 3, 2013

As you may have heard, a clinical trial of PRM-151 in patients with myelofibrosis, including primary MF, post polycythemia MF, and post essential thrombocythemia MF is now open at the centers listed below.

Read More
MPN News
Read More

Video: Pushing Research Forward

MPN News | November 7, 2013

The MPN Research Foundation has released a video on the impact PV, ET, and MF patients have had in driving MPN research forward.

Read More

MPNRF Goes to Washington

MPN News | October 26, 2013

On Thursday October 24, 2013, the MPNRF met with Representatives and Senators from around the country to deliver a message: stop sequestration now and restore funding to cancer research.

Read More

MPN BCAM 2013: Patients in Action

MPN News | September 3, 2013

Since 2000, the MPN Research Foundation has provided nearly $9 million in research funding to advance the treatment of the myeloproliferative neoplasms (essential thrombocythemia, polycythemia vera and myelofibrosis.)

Read More

Take action this September to change your prognosis.

MPN News

In 2010, The U.S. House of representatives declared September to be a time in which to raise awareness and support activities that will help people living with all types of blood cancer.

Read More

New trial recruiting PV and ET patients

MPN News | August 2013

Incyte Corp. has announced two new trials that are currently recruiting ET and PV patients:

Read More

Announcing the Chicago MPN Roundtable

MPN News | May 2011

Beginning in 2010 the MPN Research Foundation began playing host to a gathering of MPN specialists in the Chicago area, recruiting doctors from RUSH, Northwestern, University of Chicago, University of Illinois at Chicago, and Loyola.

Read More

Emmanuelle Passegue publishes on MF study

MPN News | July 15, 2013

Emmanuelle Passegue (University of California, San Francisco) has recently published results of a study of the bone marrow niche.

Read More

NEJM letter raises concern about PML and Jakafi

MPN News | July 15, 2013

Recently the New England Journal of Medicine ran a letter to the editor drawing attention to a case in which an MF patient on Jakafi suffered an incidence of progressive multifocal leukoencephalopathy (PML) after starting therapy.

Read More

New prevalence data for MPNs

MPN News

A new study by Mayo Clinic, Boston University School of Public Health, and the pharmaceutical company Sanofi’s department of Global Evidence & Value Development has found the prevalence of MPN patients living in the United States to be much higher than previously assumed.

Read More

New MPN quarterly journal launched

MPN News | July 3, 2013

Recently the MPN Forum launched a new quarterly journal focused on scientific medical advances.

Read More

MF Challenge Grants for 2013

MPN News | July 01, 2013

The MPN Research Foundation and the Leukemia & Lymphoma Society are proud to announce the winners of the second round of the MF Challenge grant program.

Read More

New data on use of Pegasys for Polycythemia Vera and Essential Thrombocythemia

MPN News | June 20, 2013

Past MPN Research Foundation grantees Srdan Verstovsek and Ross Levine contributed to a paper recently published by the American Society of Hematology which reports on a study of PV and ET patients treated with pegylated interferon alpha-2a, commonly known as Pegasys.

Read More

MF Challenge Review Meeting

MPN News | June 13, 2013

On June 1, 2013, the MPN Research Foundation and the Leukemia & Lymphoma Society brought together 13 researchers from within and outside the MPNs to review the 2nd round of MF Challenge grant proposals.

Read More

MPN news from ASCO 2013

MPN News | June 13, 2013

The American Society of Clinical Oncologist just wrapped up its annual meeting in Chicago last week.

Read More

Dr. Laura Michaelis discusses issues for PV and ET with MPN Advocacy and Education International

MPN News

Dr. Laura Michaelis of Loyola recently contributed to the MPN Advocacy and Education International's site to educate people on special issues related to Polycythemia Vera and Essential Thrombocythemia.

Read More

Panobinostat MF Trials Phase I

MPN News

Drs. Ron Hoffman and John Mascerenhas of Mt. Sinai School of Medicine in New York have reported positive outcomes from their Phase I trial of panobinostat in myelofibrosis patients.

Read More

MPN Advocacy International

MPN News

The MPN Research Foundation is pleased to announce the creation of MPN Advocacy International, a new organization founded by former VP of Development Ann Brazeau.

Read More

Biotech and Pharmaceutical Join the Fight to Fund More MPN Research

MPN News | February 25, 2012

One of the biggest challenges facing the MPN Research Foundation in its mission to broaden and accelerate MPN research is raising enough dollars to really make a difference.

Read More

MPN Fatigue Project 2013

MPN News

Fatigue is one of the most widely reported symptoms of people living with a myeloproliferative neoplasm.

Read More

Bloomberg Businessweek addresses the slow progress of drug discovery and cites the MPN Research Foundation

MPN News

When Scott Johnson read an article about a potential breakthrough that restored nerve function in mice with multiple sclerosis, he assumed it would soon be turned into a treatment.

Read More

Frankly Speaking About Cancer: MF

MPN News | December 6, 2012

In their ongoing efforts to provide support and resources to the MF community, MPN Research Foundation partner the Cancer Support Community is happy to announce a free webinar Tuesday, December 18th at 3:30 PM EST for those affected by myelofibrosis.

Read More

Women and MPN - a video by Drs. Michaelis and Mesa

MPN News

Dr. Laura Michaelis of Loyola joins Dr. Ruben Mesa of Mayo Clinic in this video.

Read More

The year in PV, ET and MF

MPN News

Since our letter to you this summer, progress has been made in clinical trials for each MPN disease group (ET, PV and MF), the promise of which is that more treatment options for all MPN patients are on the horizon. In addition, academic scientists are beginning to understand how JAK inhibitors work while at the same time combination therapies are being tested.

Read More

Ruben Mesa's Symptom Assessment Tool Helps Patients with MPN

MPN News

With funding in part by the MPN Research Foundation, researchers at Mayo Clinic in Arizona have developed a symptom assessment tool for people with Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis.

Read More

Why don't JAK Inhibitors reduce the disease burden in Myelofibrosis?

MPN News

With the discovery of JAK2 mutations and the recent approval of Ruxolitinib for individuals with myelofibrosis, there is a great deal of excitement and hope.

Read More

Tims Run Maine

MPN News | September 15, 2015

Tim Flaherty was a firefighter for 33 years with the Portland Fire Department, who passed away August 30, 2011 at only 63 years old, following a courageous fight against Myelofibrosis.

Read More

Blood Cancer Awarenss Month: Patients Working Together

MPN News

When a patient is diagnosed with myelofibrosis, polycythemia vera, or essential thrombocythemia, it can be an overwhelming and distressing message.

Read More

Governor Pat Quinn Proclaims September 20th as MF Day In Illinois

MPN News | September 11, 2012

At the urging of the MPN Research Foundation Illinois Governor Pat Quinn has proclaimed September 20th Myelofibrosis Awareness Day in Illinois!

Read More

United Health Care approves Pegasys for MPN

MPN News

Effective July 2012, United Health Care now covers Peginterferon Alfa-2a (Pegasys) for treatment of myeloproliferative neoplasms Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (MF).

Read More

Ruben Mesa discusses research and symposium

MPN News

The MPN Research Foundation in collaboration with Patient Power have released a video of Dr. Ruben Mesa speaking about one of his current research projects.

Read More

MPN Clinic - Brought to you by MPN Forum

MPN News | July 10, 2012

There's a leukemia so rare – about five cases per one million persons – that chances are you never heard of it or met anyone suffering from it.

Read More

Jakavi approved in Canada

MPN News | July 5, 2012

(PR)JAKAVI® the first medication to receive Health Canada approval to treat patients with myelofibrosis Canada Newswire

Read More

Cell Therapeutics Completes Acquisition of Pacritinib a Highly Selective JAK2 Inhibitor

MPN News

Phase 3 Study in Patients with Myelofibrosis and Low Platelet Counts Targeted to Start in Q4-2012

Read More

Update on the MF Challenge Grant Review

MPN News

On June 1st twelve experts on myelofibrosis, myeloproliferative neoplasms and fibrosis gathered around a table in a classroom at Northwestern University in Chicago.

Read More

Rare Disease Day 2012

MPN News

Today is February 29th - a day that comes every four years.

Read More

New grant opportunity for Myelofibrosis

MPN News

In January 2012 the Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia & Lymphoma Society (LLS) will jointly issue a Request for Proposals (RFP) seeking innovative approaches to reversing fibrosis in patients with myelofibrosis (MF).

Read More

Watch the West Palm Beach Patient Symposium Presentations

MPN News

On January 10 the MPN Research Foundation hosted a small patient symposium in West Palm Beach, Florida.

Read More

Seeking patients for familial MPN study

MPN News

MPN Research Foundation grantees Ben Ebert and Ann Mullally of Brigham & Women's Hospital, Harvard Medical School have been studying the causes of familial MPN.

Read More

New report from Mayo Clinic

MPN News
Read More

What are MPN Research Foundation committees?

MPN News

A typical non-profit structure includes a board of directors, who oversee the organization at a high level and ensure the mission is being pursued, and staff, who execute the vision of the board.

Read More

Women and MPNs

MPN News
Read More

Eli Lily announces data for Phase I of JAK2 inhibitor trial

MPN News

At the recent ASH meeting, pharmaceutical company Eli Lily announced findings from their Phase I trial for LY2784544, a JAK2 inhibitor.

Read More

Letter from our Vice President of Development

MPN News

Each year when preparing this letter, the reality of our accomplishments and the progress in the entire MPN community leave us with a great sense of pride and renewed hope for the future.

Read More

MPN Research Foundation Initiates Cancer Center Visits

MPN News

MPN Research Foundation visits Cancer Centers across the country to meet with their hematology groups to share information about the Foundation including the research we fund into the myeloproliferative neoplasms, educational symposia for myeloproliferative neoplasms patients, and brief updates on clinical trials for myeloproliferative neoplasms.

Read More

Financial Assistance for MPN Patients

MPN News

The MPN Research Foundation does not have a program to assist with expenses. However, there are several organizations that can help patients cover cost of treatment:

Read More

SBio JAK2 inhibitor clinical trials October 2011

MPN News

SINGAPORE, Oct. 25, 2011 - S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF).

Read More

Bay Area MPN Symposium 2010

MPN News

In May 2010, the MPD Foundation hosted an educational symposium for over 100 patients and guests in San Mateo, California.

Read More

Al Bolea Memorial Bike Ride

MPN News

In 2006 Al Bolea passed away from myelofibrosis. As Al was an avid cycliest, each year since his friends and family have gathered to celebrade his life and raise money for MPN research by hosting a charity bicycle ride.

Read More

MDS / MPN Rounds 2011

MPN News | September 13, 2011

The Aplastic Anemia & MDS International Foundation and the MPN Research Foundation presented the inaugural MDS/MPN Rounds program at the Doubletree Hotel in downtown Chicago.

Read More

MPN Research Foundation launches new website

MPN News

Thank you for joining us on our new website, or what we did this summer.

Read More

Selected Abstracts Funded by MPD Foundation 2000-Present, Presented in Chronological Order

MPN News
Read More

MPD Foundation Sponsors New Epidemiology Study

MPN News

If you or someone you know has a Philadelphia Chromosome Negative Myeloproliferative Disorder (Polycythemia Vera, Essential Thrombocythemia or Chronic Idiopathic Myelofibrosis), you've probably been told it's a rare or "orphan" disease, with one or two cases per 100,000 people. That has been the common wisdom for decades - and it may be way off the mark.

Read More

2011 MPN Research Foundation

MPN News | February 2011

The MPN Research Foundation (formerly MPD Foundation) is pleased to announce the recipients of its Established Investigator and New Investigator grants for 2011.

Read More

Request for Proposals

MPN News
Read More

Cytopia Appoints Study Chairman for JAK2 Clinical Trial

MPN News | July 30, 2008

Pharmalive.com, July 30, 2008 - Dr Tefferi is a world-renowned expert in the treatment of myeloproliferative disorders (MPDs) and has authored over 500 research publications and given many hundreds of invited lectures in haematology.

Read More

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

MPN News

This is an abstract that was presented at ASH's annual meeting on Sunday, December 7, 2008: 4:45 PM 304-306-308 - South (Moscone Center)

Read More

2009 Grant Announcement

MPN News

The MPD Foundation is pleased to announce the recipients of our Research Alliance and New Investigator grants for 2009.

Read More

CeMM Identifies Inherited Susceptibility for a Blood Malignancy

MPN News

Important discovery at the Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM): In cooperation with the Medical University of Vienna, CeMM scientists show that a common gene variant increases the risk of developing a certain type of blood malignancy.

Read More

American Society of Hematology Convention 2009

MPN News

Each year the American Society of Hematology (ASH) hosts their annual convention, where researchers, doctors and organizations such as the MPD Foundation gather to discuss the ever changing world of blood disorders and learn about the progress of research.

Read More

ASH news on Myeloproliferative Disorders

MPN News
Read More

Novartis drug

MPN News
Read More

Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options

MPN News

Approvals Represent First Time a Regulatory Authority has Simultaneously Approved One Targeted Medicine for Five Disorders Now Approved for the Solid Tumor Cancer, Dermatofibrosarcoma Protuberans US Approval Also Granted for Treatment of Four Blood Diseases: Multiple Approvals in Only Five Years Highlight new Approach of Developing Treatments Based on Common Molecular Pathways

Read More

EXELIXIS WINNING PHASE I RACE

MPN News | May 24, 2007

At a time when pharma productivity is declining, anticancer specialists Exelixis has started more Phase I clinical trials this year than any other company.

Read More

Exelixis Reports Data From Ongoing Phase 1 Study Of XL019 To Treat Myelofibrosis - Update

MPN News

12/10/2007 2:06:40 PM Monday afternoon, Exelixis, Inc. (EXEL), a developer of therapies for the treatment of cancer and other serious diseases, announced data from an ongoing Phase 1 trial of XL019 to treat patients with myelofibrosis, a myeloproliferative disorder, or MPD.

Read More

JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients

MPN News

Australian and New York based company Cytopia Limited announced today that its lead JAK2 inhibitor compound CYT387 has demonstrated potent activity in cells isolated from patients with myeloproliferative disorders (MPDs).

Read More

TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients

MPN News

San Diego, CA – January 31, 2008 - TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases.

Read More

Incyte Reports Progress in Multiple Clinical Programs and Expands JAK Inhibitor Program

MPN News

Wilmington, Del. -- (Business Wire) -- Incyte Corporation (Nasdaq: INCY) today reported full year and fourth quarter 2007 financial results, and announced its 2008 financial guidance and key objectives and plans for its rapidly expanding clinical pipeline.

Read More

Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders

MPN News | March 18, 2008

Cytopia Limited (ASX:CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs).

Read More

UCSD, TargeGen team-up on blood disease treatment

MPN News | April 7, 2008

A one-year scientific collaboration that included the University of California San Diego and the tiny local biotechnology company TargeGen has moved a treatment for a potentially fatal blood disease into human trials at record speed.

Read More

Incyte's Novel JAK Inhibitor Demonstrates Rapid Clinical Benefits in Ongoing Phase I/II Myelofibrosis Study

MPN News | June 2, 2008

Results Presented June 2, 2008 at the 2008 American Society of Clinical Oncology Annual Meeting

Read More

Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates Rapid and Durable Clinical Benefits in Myelofibrosis Patients - Data presented at ASH Annual Meeting in San Francisco 2008

MPN News | December 6, 2008

Incyte Corporation (Nasdaq: INCY) will present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase (JAK) inhibitor, in patients with myelofibrosis (MF) at the 50th American Society of Hematology (ASH) Annual Meeting.

Read More

Incyte Reaches Agreement with FDA on MF Drug

MPN News | July 22, 2009

The COMFORT-1 (COntrolled MyeloFibrosis Study with ORal Jak Treatment) trial will test the drug INCB18424 in patients with Primary Myelofibrosis, post-Polycythemia Vera Myelofibrosis or post-Essential Thrombocythemia Myelofibrosis.

Read More

Novartis enters into partnership with Incyte

MPN News

Novartis will collaborate with Incyte on the further development of two of Incyte Corp.'s compounds including the JAK2 Inhibitor INCB18424 currently in Phase III of the clinical trials process.

Read More

Study Links ESAs to Higher Leukemia Risk for Some

MPN News

Erythropoiesis-stimulating agents (ESAs), such as Aranesp, Epogen and Procrit, may increase the risk of acute leukemia in patients with a certain bone marrow disorder, researchers reported at the American Society of Hematology's annual meeting in Atlanta.

Read More

Grant Awards

MPN News

MPD Research Alliance:

Read More

MPD Gene Mutation Discovered!

MPN News

The first news came out on March 17, 2005: A team of researchers at the Cambridge Institute for Medical Research, UK, led by Dr. Tony Green, announced that they had discovered a single point mutation in the JAK2 gene that appeared in 97% of polycythemia vera patients they studied, in 57% of essential thrombocythemia patients and in 50% of patients with idiopathic myelofibrosis.

Read More

After Discovering the JAK2 Mutation: Next Steps in Developing Targeted Treatments for PV, ET and MF

MPN News

An interview with D. Gary Gilliland, PhD, MD

Read More

MPD Foundation funds research for incurable blood disorders

MPN News

The Myeloproliferative Disorders Foundation has awarded $750,000 to establish the MPD Research Alliance, a collaboration of the University of Illinois at Chicago, Harvard Medical School and Mayo Clinic to accelerate drug development for incurable, progressive bone marrow disorders.

Read More

UIC joins forces with Harvard, Mayo Clinic to battle bone marrow disorders

MPN News

The Myeloproliferative Disorders Foundation awarded $750,000 to establish the MPD Research Alliance, a collaboration between UIC, Harvard Medical School and Mayo Clinic to accelerate drug development for incurable, progressive bone marrow disorders.

Read More

UIC RECEIVES $20 MILLION NCI GRANT TO RESEARCH BLOOD DISORDERS

MPN News

* Excerpts from UIC news release of September 6, 2006, announcing the NCI grant to the MPD International Research Consortium

Read More

Discovery of a new mutation in JAK2V617F negative myelofibrosis patients

MPN News

Many patients with polycythemia vera (PV), essential thrombocythemia (ET) or myelofibrosis (MF) have the JAK2V617F mutation. This finding has reinvigorated and revolutionized research on these MPDs.

Read More

University of Utah to Investigate Blood Disorders

MPN News

The University of Utah will receive more than $2 million over five years to investigate the causes of several incurable blood disorders.

Read More

Researchers Advancing Blood Cancer Therapies Receive $42.75 Million in Grants From The Leukemia & Lymphoma Society

MPN News

WHITE PLAINS, N.Y., Oct. 23 /PRNewswire/ -- The Leukemia & Lymphoma Society today announced it has awarded four new Specialized Center of Research (SCOR) grants, the Society's most ambitious and synergistic research initiative, bringing the program's total funding to $159 million since its inception in 2000.

Read More

Gene Mutation Predicts Outcome in Blood Disorder

MPN News | December 10, 2007

ORLANDO, Fla., Dec. 10 /PRNewswire/ -- Both the cause and cure for polycythemia vera, a disorder of uncontrolled blood cell production, remain elusive, but researchers from the University of Florence, Italy, may be a step closer to both.

Read More

Top Scientists to Receive Prestigious Awards From the American Society of Hematology

MPN News | December 12, 2007

Atlanta, Dec. 5 -- The American Society of Hematology (ASH), the world's largest professional society of blood specialists, is honoring three scientists who have made notable contributions to the genetic understanding of disease.

Read More

New Cancer Discovery, Hormone to Blame

MPN News

ORLANDO, Fla. (Ivanhoe Newswire) -- A breakthrough discovery reveals one particular hormone is responsible for helping a cancer enzyme cause a type of deadly red blood cell cancer.

Read More

Major grant awarded for leukemia & myelofibrosis

MPN News

The California Institute for Regenerative Medicine has awarded a group of researchers $20 million for work on six compounds.

Read More

Study published on new prognostic tool

MPN News

The International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) is comprised of hematologists, hematopathologists, and laboratory scientists.

Read More

Report on JAK2 community screening in Pennsylvania

MPN News

The Agency for Toxic Substances and Disease Registry (ATSDR) has published results of the community wide JAK2 screening conducted in Schuylkill, Carbon and Luzerne counties in PA.

Read More

Announcing Challenge Grant 2011

MPN News

The MPD Foundation is pleased to announce a Call for Proposals for its 2011 Challenge Grant Program.

Read More

Sanofi-Aventis purchases TargeGen, developer of drugs for Myeloproliferative Disorders

MPN News

TargeGen, producer of JAK2 inhibitor TG101348, was purchased on June 30 2010 by French pharmaceutical company Sanofi-Aventis.

Read More

Incyte approved by FDA for special PV protocol

MPN News | September 2010

The FDA has approved a special protocol for Incyte's clinical trial for Polycythemia Vera patients.

Read More

ASH press release on blood clot risk prediction model

MPN News

The September 2010 issue of Blood included an article on a new model for estimating risk of blood clot for a variety of cancer patients.

Read More

Report on JAK2 prevalence among MPD patients in India

MPN News | October 2010

The Indian Journal of Medical Research recently published an article reporting the prevalence of the JAK2 mutation among polycythemia vera, essential thrombocythemia and myelofibrosis patients at a clinic in northern India.

Read More

SBio granted orphan designation for Myelofibrosis drug

MPN News | October 2010

SBio, based in Singapore, is working on a JAK2 Inhibitor for Myelofibrosis patients, SB1518.

Read More

MPD doctors discuss benefits of 2 JAK2 Inhibitors

MPN News | December 2010

Drs. Ayalew Tefferi and Animesh Pardanani presented data at ASH on the benefits of two drugs currently in clinical trials: TG101348 and CYT387.

Read More

Incyte reports positive results of JAK Inhibitor tested in Essential Thrombocythemia and Polycythemia Vera patients

MPN News | December 2010

Incyte Corp. is currently working on phase II clinical trials for their JAK Inhibitor INCB18424.

Read More

SBio drug shows promise for symptom and spleen reduction for myelofibrosis patients

MPN News | December 2010

Data from SBio's ongoing clinical trial for their JAK2 Inhibitor SB1518 was reported at the recent annual meeting of the American Society of Hematology.

Read More

MPD Chat archives ASH abstracts

MPN News | December 2010

Online chat and support group MPD-Chat has listed all abstracts presented at the recent American Society of Hematology meeting that are relevant to MPD/MPN.

Read More

ASCO releases videos of experts discussing MPDs

MPN News | December 2010

The American Society of Clinical Oncology (ASCO) recently released three videos of renowned MPD specialists discussing various topics related to MPDs. Drs. Ayalew Tefferi, William Vainchencker and James Vardiman contributed to the series.

Read More

Geron enrolls first patient in drug study for essential thrombocythemia

MPN News | January 2011

Geron Corporation has enrolled their first person in a Phase 2 clinical trial to test their drug (GRN163L) in patients with essential thrombocythemia.

Read More

European journal offers review of current JAK Inhibitors

MPN News | April 2011

he Belgian Journal of Hematology recently published their review of the state of JAK Inhibitors.

Read More

Patients push researchers to share data

MPN News | March 2011

The patients who run the MPD Foundation are impatient to see results from the medical research they fund.

Read More

MPN research pays off as new MPN drugs advance to market: a report from ASCO

MPN News | June 2011

June's American Society of Clinical Oncology (ASCO) conference in Chicago demonstrated that investments in MPN Research are starting to pay off as multiple drugs move through the drug development pipeline.

Read More

Incyte nears the finish line for first FDA approved treatment for myelofibrosis

MPN News | June 2011

During ASCO's annual meeting Incyte announced that it has submitted a New Drug Application (NDA) for Ruxolitinib to the US Food and Drug Administration.

Read More

Letter from the President

MPN News

I can't believe it's been five years since we started the MPD Foundation.

Read More

MPD Foundation President, Bob Rosen, attends 2004 ASH Conference in San Diego, California

MPN News

I attended the Saturday sessions of the ASH conference in San Diego and wanted to make a brief report of my impressions.

Read More

Bike ride fund-raiser in memory of Belmont cyclist

MPN News | Thursday, July 20, 2006

Belmont resident Al Bolea lost his gallant seven-year fight against myelofibrosis at age 47.

Read More

I5 weeks after health collapse, coach back in beloved routine

MPN News | March 19, 2006

EUSTIS -- The sounds of baseball were all around Chet Lemon and it was music to his ears.

Read More

MPD Foundation Initiates Relationship with the FDA

MPN News

It is clear in the research community that there's a great deal of excellent work happening in the direction of new therapies for MPD patients.

Read More

The MPD Foundation Grows Awareness and Outreach to the MPD Patient Community

MPN News

The MPD Foundation acts as a great resource for patients and those wishing to host MPD Patient Support groups across the U.S. and in other countries.

Read More

In Memory of Joyce Niblack

MPN News

Joyce Niblack may have been the truest friend the MPD community will ever have.

Read More

Rare cancer in northeast Pa. subject of $5.5 million study

MPN News | March 12, 2009

ALLENTOWN - Residents of an environmentally degraded region of eastern Pennsylvania say they're looking forward to finally getting answers now that Congress has approved millions to study the first known cluster of a rare blood cancer.

Read More

Upcoming: Al Bolea Memorial Ride and Barbeque

MPN News | July 14, 2009

In 2006, Al Bolea passed away from Myelofibrosis. Every year since, his friends and family have gathered to celebrate his life and raise money for MPD research. The Al Bolea Memorial Ride and BBQ will take place on Sunday, August 16th 2009.

Read More

Latest Findings Released in Polycythemia Vera Investigation by the Agency for Toxic Substances and Disease Registry

MPN News | December 8, 2009

Following two rounds of community health screening in northeastern Pennsylvania for the JAK2 genetic marker, 19 (1.6%) of the 1,170 people tested were found to have this mutation.

Read More

Feel the Need - Feed the Cure

MPN News

February 2010 Participants

Read More

Update on Feel the Need - Feed the Cure

MPN News

In February, the MPD Foundation launched its first fundraising initiative, Feel the Need – Feed the Cure. All proceeds went to the MPD Foundation for research aimed at finding a cure and better treatment options for polycythemia vera, myelofibrosis and essential thrombocythemia.

Read More

CDC funds multi-disciplinary research on PV

MPN News

The MPD community has been anticipating the release of news on plans for the $5.5 million awarded to study the PV outbreak in Pennsylvania. MPD Foundation funded researchers such as Drs. Ronald Hoffman and Mingjiang Xu are among those selected to investigate various components of the multi-disciplinary research that will be pursued with the award.

Read More

Polycythemia Vera: A Patient's Son Reports

MPN News

MPD Foundation board member, Sam Klepper, was interviewed by his son Jake for a recent school project on human diseases.

Read More

Annette DeBow's Trek for a Cure starts this week!

MPN News

Annette DeBow, a polycythemia vera patient, will begin hiking the High Sierras on July 15 2010. Her goal is to raise money for MPD research with the MPD Foundation as the recipient of her effort.

Read More

Pennsylvanians meeting September 22nd to get educated on PV

MPN News | September 2010

The Tri-County Polycythemia Vera Community Advisory Committee was formed as a result of the discovery of a cluster of Polycythemia Vera (PV) patients in Luzerne, Schuylkill and Carbon counties in Pennsylvania.

Read More

For Pete's Sake: An MF patient's step-daughter goes after a cure for Myeloproliferative Disorders

MPN News

After Nora Sutton's step-father Pete was diagnosed with Myelofibrosis she decided to do something about it. Knowing that more research is needed to provide better care and treatments for MPD patients, Nora took it upon herself to sign up for the Hartford Half Marathon in October.

Read More

September edition of MPD Life

MPN News

Like the MPD Foundation, the United Kingdom's MPD-Support has a free newsletter available to patients and other members of the MPD community.

Read More

White Paper: Nature, Nurture, or Both?

MPN News | October 2010

Eileen Wiggins is a practical woman, straightforward, no nonsense. So when she started feeling tired most all the time and losing a little weight – not that she couldn't afford to drop a few pounds here and there but for her age she was doing a lot better than some others she knew – she headed straight for the downtown clinic for testing.

Read More

Myelofibrosis patient draws strength from celebration

MPN News | October 2010
Read More

MPN Research Foundation's San Diego Symposium Brings the Experts to the Patients

MPN News | November 2010

The MPD Foundation hosted a patient educational symposium in San Diego on October 25, 2010 at the UCSD Moores Cancer Center in La Jolla.

Read More

Questions remain on Pennsylvania PV cluster

MPN News | May 2011

The cluster of polycythemia vera that has been identified in the area surrounding a Superfund site in Pennsylvania has produced some questions on whether PV may be under-diagnosed.

Read More

MPN Forum Launches

MPN News | June 2011

A new internet monthly MPN magazine, MPN Forum was pubished Wedsnesday, June 15.

Read More

Newsletter Archive

MPN News
Read More

Get educated on MF, PV and ET

Sign up for MPN patient stories, news updates and events.

x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe